cangrelor

Known as: N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid), [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
BACKGROUND The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
CONTEXT Thienopyridines are among the most widely prescribed medications, but their use can be complicated by the unanticipated… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2012
2012
Cangrelor is an intravenous antagonist of the P2Y12 receptor characterized by rapid, potent, predictable, and reversible platelet… (More)
  • table 2
  • table 1
  • figure 4
  • figure 2
  • figure 3
Is this relevant?
2012
2012
BACKGROUND Despite robust efficacy in the reduction of ischemic events in patients who require percutaneous coronary intervention… (More)
  • figure 1
  • table I
  • figure 2
  • table III
  • table IV
Is this relevant?
2010
2010
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cangrelor… (More)
  • table I
  • table II
  • figure 1
  • table III
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an intravenous blocker of the adenosine diphosphate… (More)
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Cangrelor is a direct, parenteral, and reversible inhibitor of the platelet P2Y12 receptor currently undergoing Phase… (More)
Is this relevant?
Review
2008
Review
2008
ADP and ATP play a crucial role in platelet activation and their receptors are potential targets for antithrombotic drugs. The… (More)
  • figure 1
Is this relevant?
Review
2001
Review
2001
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the… (More)
Is this relevant?